Physician profile
Michael C Yeates
NPI 1336394410
$4,680.84
in general payments reported to CMS, 2019-2025
42 companies · $873 in 2025
The $873 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $439 · 2021: $652 · 2022: $534 · 2023: $800 · 2024: $839 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,447 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.47 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,021.94 | 2020-2025 | Vraylar, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $485.54 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $301.76 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $259.24 | 2020-2022 | |
| Novo Nordisk INC | $239.74 | 2019-2025 | Wegovy, Ozempic |
| Pfizer INC. | $221.44 | 2019-2025 | |
| Lilly USA, LLC | $212.09 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $205.82 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.52 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $159.19 | 2019-2025 | Spravato |
| Phathom Pharmaceuticals, INC. | $117.35 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $109.45 | 2020-2024 | Vaxneuvance, Gardasil 9, Pneumovax 23 |
| Dynavax Technologies Corporation | $99.77 | 2021-2025 | Heplisav-B |
| Axsome Therapeutics, INC. | $86.21 | 2023-2024 | Sunosi |
| Strongbridge US INC. | $85.23 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yeates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.